The epigenetics of ovarian cancer drug resistance and resensitization

摘要: Ovarian cancer is the most lethal of all gynecologic neoplasms. Early-stage malignancy frequently asymptomatic and difficult to detect thus, by time diagnosis, women have advanced disease. Most these patients, although initially responsive, eventually develop succumb drug-resistant metastases. The success typical postsurgical regimens, usually a platinum/taxane combination, limited primary tumors being intrinsically refractory treatment responsive becoming treatment, due emergence tumor cells. This review highlights prominent role for epigenetics, particularly aberrant DNA methylation histone acetylation, in both intrinsic acquired drug-resistance genetic pathways ovarian cancer. Administration therapies that reverse epigenetic "silencing" suppressors other genes involved drug response cascades could prove useful management patients. In this review, we summarize recent advances use methyltransferase deacetylase inhibitors possible synergistic combinations achieve maximal suppressor gene re-expression. Moreover, when used combination with conventional chemotherapeutic agents, epigenetic-based may provide means resensitize proven cytotoxic activities chemotherapeutics.